MC
ICPT

Manteio Capital’s Intercept Pharmaceuticals, Inc. ICPT Stock Holding History

Manteio Capital’s Portfolio ICPT Stock Details ICPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-12,628
Closed -$206K – 226
2021
Q4 		$206K Buy
+12,628
New +$213K 0.27% 176

Other funds holding ICPT

State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Manteio Capital's ICPT Position: Q1 2022 in Review

Manteio Capital sold out of Intercept Pharmaceuticals, Inc. (ICPT) in Q1 2022, closing a stake of 12,628 shares — an estimated $206K sold.

Manteio Capital first reported a position in ICPT in Q4 2021 and held it in 1 quarter. The position peaked at $206K in Q4 2021. 148 funds tracked by Wall St. Rank hold ICPT as of Q1 2022.

  • Manteio Capital reported no remaining Intercept Pharmaceuticals, Inc. position as of Q1 2022 after selling out during the quarter.
  • Manteio Capital sold 12,628 Intercept Pharmaceuticals, Inc. shares in Q1 2022, an estimated $206K.
  • Manteio Capital first reported a position in Intercept Pharmaceuticals, Inc. in Q4 2021 and held it in 1 quarter.
  • Manteio Capital's Intercept Pharmaceuticals, Inc. position peaked at $206K in Q4 2021.
  • 148 funds tracked by Wall St. Rank held Intercept Pharmaceuticals, Inc. as of Q1 2022.

Based on Manteio Capital's 13F filing for Q1 2022.